Literature DB >> 2132556

Tamoxifen-associated endometrial carcinoma in postmenopausal breast cancer patients.

J H Malfetano1.   

Abstract

Tamoxifen citrate, a nonsteroidal antiestrogen with agonistic properties, is prescribed as an adjuvant to surgery in the treatment of breast cancer. Recent reports have suggested that tamoxifen has an estrogenic property and may be implicated in the development of endometrial carcinomas. Seven new cases are reported to the existing literature in which endometrial carcinomas developed in postmenopausal women on tamoxifen therapy for breast carcinomas.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2132556     DOI： 10.1016/0090-8258(90)90404-9

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


  10 in total

1.  Suppression of Estrogenic Activity by Medroxyprogesterone Acetate in Tamoxifen-treated Patients after Surgery for Breast Cancer to Reduce the Risk of Endometrial Cancer Development.

Authors: 
Journal:  Breast Cancer       Date:  1996-03-29       Impact factor: 4.239

Review 2.  Tamoxifen: a review of pharmacoeconomic and quality-of-life considerations for its use as adjuvant therapy in women with breast cancer.

Authors:  H M Bryson; G L Plosker
Journal:  Pharmacoeconomics       Date:  1993-07       Impact factor: 4.981

3.  Tamoxifen and cancer of the endometrium.

Authors:  G O'Connell; A Arnold
Journal:  CMAJ       Date:  1993-06-15       Impact factor: 8.262

4.  Endometrial pathology in postmenopausal tamoxifen treatment: comparison between gynaecologically symptomatic and asymptomatic breast cancer patients.

Authors:  I Cohen; E Perel; D Flex; R Tepper; M M Altaras; M Cordoba; Y Beyth
Journal:  J Clin Pathol       Date:  1999-04       Impact factor: 3.411

5.  The effect of tamoxifen on the endometrium.

Authors:  B Uziely; A Lewin; G Brufman; D Dorembus; S Mor-Yosef
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

Review 6.  Gynaecologic effects of tamoxifen.

Authors:  D Y Kuo; C D Runowicz
Journal:  Med Oncol       Date:  1995-06       Impact factor: 3.064

Review 7.  What do we know and what don't we know about tamoxifen in the human uterus.

Authors:  A Friedl; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 8.  A risk-benefit assessment of tamoxifen therapy.

Authors:  W H Catherino; V C Jordan
Journal:  Drug Saf       Date:  1993-05       Impact factor: 5.606

9.  Endometrial evaluation by ultrasonography, hysteroscopy and histopathology in cases of breast carcinoma on Tamoxifen therapy.

Authors:  Alka Jindal; Manjit K Mohi; Manjeet Kaur; Balwinder Kaur; Risham Singla; Shaunik Singh
Journal:  J Midlife Health       Date:  2015 Apr-Jun

10.  Effect of long-term treatment with steroid hormones or tamoxifen on the progesterone receptor and androgen receptor in the endometrium of ovariectomized cynomolgus macaques.

Authors:  Hong Wang; Erika Isaksson; Bo von Schoultz; J Mark Cline; Lena Sahlin
Journal:  Reprod Biol Endocrinol       Date:  2003-02-05       Impact factor: 5.211
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.